氢氯噻嗪使用与非黑色素瘤皮肤癌风险:丹麦全国病例对照研究
该研究基于丹麦癌症登记和处方登记数据,采用病例对照设计,评估氢氯噻嗪累积使用与非黑色素瘤皮肤癌风险的关系。结果显示,氢氯噻嗪高累积剂量与基底细胞癌和鳞状细胞癌风险升高相关,且存在剂量反应关系,尤其鳞状细胞癌风险显著增加。
要点
- 氢氯噻嗪高累积用量(≥50,000 mg)与基底细胞癌风险升高相关(OR 1.29)。
- 氢氯噻嗪高累积用量与鳞状细胞癌风险显著升高相关(OR 3.98)。
- 氢氯噻嗪使用与基底细胞癌和鳞状细胞癌均呈剂量反应关系。
核心结论
- 氢氯噻嗪使用与非黑色素瘤皮肤癌风险显著增加相关,尤其是鳞状细胞癌。
研究设计与样本
- 基于丹麦癌症登记(2004-2012年)的全国病例对照研究,对照按年龄和性别1:20匹配,从丹麦处方登记评估1995-2012年氢氯噻嗪累积使用。
主要发现
- 高用量氢氯噻嗪(≥50,000 mg)与基底细胞癌风险相关OR为1.29(95%CI 1.23-1.35)。
- 高用量氢氯噻嗪(≥50,000 mg)与鳞状细胞癌风险相关OR为3.98(95%CI 3.68-4.31)。
- 最高累积剂量类别(≥200,000 mg)基底细胞癌OR为1.54(95%CI 1.38-1.71),鳞状细胞癌OR为7.38(95%CI 6.32-8.60)。
- 其他利尿剂和降压药使用与非黑色素瘤皮肤癌无关联。
关键数值与推荐
- 高用量定义为累积氢氯噻嗪≥50,000 mg。
- 最高累积剂量类别为≥200,000 mg。
- 氢氯噻嗪使用与基底细胞癌和鳞状细胞癌均存在明确剂量反应关系。
临床怎么用
- 处方氢氯噻嗪时应关注患者皮肤癌风险,尤其长期高累积剂量者。
- 对使用氢氯噻嗪的患者建议加强皮肤监测和防晒措施。
局限性
- 研究缺乏日光暴露数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hydrochlorothiazide, one of the most frequently used diuretic and antihypertensive drugs in the United States and Western Europe, is photosensitizing and has previously been linked to lip cancer. OBJECTIVE: To examine the association between hydrochlorothiazide use and the risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). METHODS: From the Danish Cancer Registry, we identified patients (cases) with nonmelanoma skin cancer (NMSC) during 2004-2012. Controls were matched 1:20 by age and sex. Cumulative hydrochlorothiazide use (in 1995-2012) was assessed from the Danish Prescription Registry. Using conditional logistic regression, we calculated odds ratios (ORs) for BCC and SCC associated with hydrochlorothiazide use. RESULTS: High use of hydrochlorothiazide (≥50,000 mg) was associated with ORs of 1.29 (95% confidence interval [CI], 1.23-1.35) for BCC and 3.98 (95% CI, 3.68-4.31) for SCC. We found clear dose-response relationships between hydrochlorothiazide use and both BCC and SCC; the highest cumulative dose category (≥200,000 mg of HCTZ) had ORs of 1.54 (95% CI, 1.38-1.71) and 7.38 (95% CI, 6.32-8.60) for BCC and SCC, respectively. Use of other diuretics and antihypertensives was not associated with NMSC. LIMITATIONS: No data on sun exposure were available. CONCLUSIONS: Hydrochlorothiazide use is associated with a substantially increased risk of NMSC, especially SCC.
引用
- Pedersen SA, Gaist D, Schmidt SAJ, et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2017. PMID: 29217346. doi:10.1016/j.jaad.2017.11.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。